Goldman Sachs Comments on Medtronic

Goldman Sachs has published a research report on Medtronic WSM. In the report, Goldman Sachs wrote, "Medtronic reported 1QFY12 adjusted EPS of $0.79 (vs. $0.80 in the year ago quarter) – lower than our estimate of $0.81 and in line with consensus. The reported top line revenue of $4.049 billion (+7% yoy; +2% FXN) was $27mn above our estimate and $71mn above consensus." Goldman Sachs rated Medtronic a Neutral with no price target given in this report, despite the fact that the PT was reiterated. Medtronic closed Monday at $31.18.